Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    23527958 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
Condition: Hemophagocytic Lymphohistiocytosis
Intervention: Drug: tocilizumab
2 Recruiting Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia
Conditions: Recurrent B-Cell Tumor;   Refractory B-Cell Tumor
Intervention: Biological: CD19-specific chimeric antigen receptor

Study has passed its completion date and status has not been verified in more than two years.